Q-omics provides the consensus-scored H2BC16P profile across patient tissues and cancer cell-line models. H2BC16P expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, H2BC16P is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, H2BC16P RNA expression shows 8,833 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, BLCA, and THYM as cancer lineages where H2BC16P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H2BC16P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H2BC16P survival associations across molecular data types. H2BC16P RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H2BC16P RNA expression–survival associations across cancer types. High H2BC16P expression shows unfavorable associations in COAD, KIRC, ACC, BLCA and LIHC, but favorable associations in GBM. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for H2BC16P RNA expression.
This table summarizes H2BC16P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for H2BC16P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H2BC16P shows higher tumor expression in BLCA, HNSC, LIHC, BRCA, LUSC and LUAD. The BLCA box plot shows higher H2BC16P RNA expression in tumor versus normal tissue (log2 FC = +0.306, t-test p < 0.001).
This table shows molecular features associated with H2BC16P in patient tissues and cancer cell lines. In patient samples, H2BC16P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
